AC Immune (ACIU) Receivables - Accured (2014 - 2026)

AC Immune (ACIU) has 13 years of Receivables - Accured data on file, last reported at $293.7 million in Q1 2026.

• On a quarterly basis, Receivables - Accured rose 28448.02% year-over-year to $293.7 million in Q1 2026; TTM through Mar 2026 was $293.7 million, a 28448.02% increase from a year earlier, with the FY2025 full-year figure at $434.2 million, up 34511.0% from the prior year.
• Receivables - Accured for Q1 2026 stood at $293.7 million, down from $450.4 million in the prior quarter.
• Over the last five years, Receivables - Accured for ACIU reached as high as $450.4 million in Q4 2025 and fell as low as $51772.8 in Q3 2022.
• Historically, Receivables - Accured has averaged $96.6 million across 5 years, with a median of $750718.5 in 2023.
• Across the five-year window, Receivables - Accured slumped 99.96% in 2022 and surged 65383.05% in 2023, its largest moves.
• Year by year, Receivables - Accured stood at $423512.9 in 2022, then jumped by 65383.05% to $277.3 million in 2023, then plunged by 99.55% to $1.3 million in 2024, then surged by 35803.5% to $450.4 million in 2025, then slumped by 34.79% to $293.7 million in 2026.
• Per Business Quant data, the three most recent Receivables - Accured figures were $293.7 million in Q1 2026, $450.4 million in Q4 2025, and $502544.0 in Q3 2025.